SRX251, or SRX-251, also known as API-251, is a selective vasopressin V1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.